Meet Our CMO
PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer.
Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies. He has held positions as medical adviser, principal scientist, project manager and clinical pharmacology director. Areas of expertise span through preclinical R&D, translational sciences, and clinical development, including clinical evaluation of in-licensing opportunities.
As trained pharmacokineticist, he has routinely developed and utilised modelling and simulation techniques to facilitate studydesign and data evaluation. At present, he is based at the Clinical trials unit/Department of clinical pharmacology at Karolinska university hospital.
Meet Our CMO
PharmNovo is pleased to announce the appointment of Olof Breuer MD, PhD, Specialist in Clinical Pharmacology, who will be acting as our Chief medical officer.
Olof has over 25 years of experience in Pharmaceutical R&D, where of 17 years within big and small pharmaceutical companies. He has held positions as medical adviser, principal scientist, project manager and clinical pharmacology director. Areas of expertise span through preclinical R&D, translational sciences, and clinical development, including clinical evaluation of in-licensing opportunities.
As trained pharmacokineticist, he has routinely developed and utilised modelling and simulation techniques to facilitate studydesign and data evaluation. At present, he is based at the Clinical trials unit/Department of clinical pharmacology at Karolinska university hospital.
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more